Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation
- PMID: 34265259
- PMCID: PMC11379041
- DOI: 10.1016/S1473-3099(20)30871-9
Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation
Abstract
The most severe consequences of dengue virus infection include shock, haemorrhage, and major organ failure; however, the frequency of these manifestations varies, and the relative contribution of pre-existing anti-dengue virus antibodies, virus characteristics, and host factors (including age and comorbidities) are not well understood. Reliable characterisation of the epidemiology of severe dengue first depends on the use of consistent definitions of disease severity. As vaccine trials have shown, severe dengue is a crucial interventional endpoint, yet the infrequency of its occurrence necessitates the inclusion of thousands of study participants to appropriately compare its frequency among participants who have and have not been vaccinated. Hospital admission is frequently used as a proxy for severe dengue; however, lack of specificity and variability in clinical practices limit the reliability of this approach. Although previous infection with a dengue virus is the best characterised risk factor for developing severe dengue, the influence of the timing between dengue virus infections and the sequence of dengue virus infections on disease severity is only beginning to be elucidated. To improve our understanding of the diverse factors that shape the clinical spectrum of disease resulting from dengue virus infection, prospective, community-based and clinic-based immunological, virological, genetic, and clinical studies across a range of ages and geographical regions are needed.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests KBA reports serving as a consultant for Emergent Biosolutions and Eli Lilly, outside of the submitted work. EH reports grants from the National Institute of Allergy and Infectious Diseases (National Institutes of Health), during the conduct of this Personal View. LCK reports grants from the National Institutes of Health, during the conduct of this Personal View. ACM reports grants from the National Institutes of Health, during the conduct of this Personal View. All other authors declare no competing interests.
Figures
Similar articles
-
Impact of dengue virus infection and its control.FEMS Immunol Med Microbiol. 1997 Aug;18(4):291-300. doi: 10.1111/j.1574-695X.1997.tb01058.x. FEMS Immunol Med Microbiol. 1997. PMID: 9348165
-
Severe dengue: the need for new case definitions.Lancet Infect Dis. 2006 May;6(5):297-302. doi: 10.1016/S1473-3099(06)70465-0. Lancet Infect Dis. 2006. PMID: 16631550 Review.
-
The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries.PLoS Negl Trop Dis. 2016 Dec 21;10(12):e0005179. doi: 10.1371/journal.pntd.0005179. eCollection 2016 Dec. PLoS Negl Trop Dis. 2016. PMID: 28002420 Free PMC article.
-
Unusual, neurological and severe dengue manifestations during the outbreak in Sri Lanka, 2017.J Clin Virol. 2020 Apr;125:104304. doi: 10.1016/j.jcv.2020.104304. Epub 2020 Feb 27. J Clin Virol. 2020. PMID: 32145478
-
Dengue virus non-structural protein 1: a pathogenic factor, therapeutic target, and vaccine candidate.J Biomed Sci. 2018 Jul 24;25(1):58. doi: 10.1186/s12929-018-0462-0. J Biomed Sci. 2018. PMID: 30037331 Free PMC article. Review.
Cited by
-
Evaluation of remote radiologist-interpreted point-of-care ultrasound for suspected dengue patients in a primary health care facility in Colombia.Infect Dis Poverty. 2023 Sep 28;12(1):90. doi: 10.1186/s40249-023-01141-9. Infect Dis Poverty. 2023. PMID: 37759280 Free PMC article.
-
A Novel, Comprehensive A129 Mouse Model for Investigating Dengue Vaccines and Evaluating Pathogenesis.Vaccines (Basel). 2023 Dec 15;11(12):1857. doi: 10.3390/vaccines11121857. Vaccines (Basel). 2023. PMID: 38140260 Free PMC article.
-
Trends and insights in dengue virus research globally: a bibliometric analysis (1995-2023).J Transl Med. 2024 Sep 3;22(1):818. doi: 10.1186/s12967-024-05561-5. J Transl Med. 2024. PMID: 39227968 Free PMC article.
-
Extracellular Vesicles Are Conveyors of the NS1 Toxin during Dengue Virus and Zika Virus Infection.Viruses. 2023 Jan 27;15(2):364. doi: 10.3390/v15020364. Viruses. 2023. PMID: 36851578 Free PMC article.
-
Human coronavirus OC43-elicited CD4+ T cells protect against SARS-CoV-2 in HLA transgenic mice.Nat Commun. 2024 Jan 26;15(1):787. doi: 10.1038/s41467-024-45043-2. Nat Commun. 2024. PMID: 38278784 Free PMC article.
References
-
- Shepard DS, Undurraga EA, Halasa YA, Stanaway JD. The global economic burden of dengue: a systematic analysis. Lancet Infect Dis 2016; 16: 935–41. - PubMed
-
- Cattarino L, Rodriguez-Barraquer I, Imai N, Cummings DAT, Ferguson NM. Mapping global variation in dengue transmission intensity. Sci Transl Med 2020; 12: eaax4144. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials